Expand your knowledge of current techniques and indications for hepatic ablation by attending an in-person clinical education course.
In our Hepatic Ablation Masterclass, you will:
Complete the form below to receive information about upcoming classes.
Attend an event, schedule a hands-on demonstration, or stop by our booth to learn more about the Emprint™ SX ablation platform.
Complete the form below to receive information about upcoming conferences.
Indications for Use:
The Emprint™ SX Ablation Platform with Thermosphere™ Technology is intended for use in percutaneous, laparoscopic, and intraoperative coagulation (ablation) of soft tissue, including partial or complete ablation of non-resectable liver tumors. The Emprint™ SX Ablation System is not intended for use in cardiac procedures. The system’s optional, 3-D navigation feature assists in the placement of the Emprint™ SX Navigation Antenna with Thermosphere™ Technology using real-time image guidance during intraoperative and laparoscopic ablation procedures. The navigation feature enhances the output of a compatible medical ultrasound imaging system and displays an image of the antenna and its predicted trajectory on a computer monitor. The size and shape of the predicted ablation zone relative to the position of the antenna is displayed on the enhanced ultrasound image.
The Medtronic Emprint SX Ablation platform is not indicated for use in cardiac procedures. Microwave ablation procedures are not recommended for pregnant patients. Potential risks to the patient and/or fetus have not been established. Microwave ablation procedures are not recommended for patients with cardiac pacemakers or other implanted electronic devices. Potential risks have not been evaluated. Do not defibrillate a patient with an antenna inserted. Completely remove the antenna from the patient before defibrillation. Do not use the field generator during cardiac defibrillation.
Common patient risks include: blood clot, infection, injury to adjacent tissues, pain, post-ablation syndrome.
Remote patient risks include: arrhythmia, arteriovenous fistula, ascites, bleeding, cancer seeding, cardiac arrest, chronic obstructive pulmonary disease exacerbation, hematoma, hemolysis, hepatic infarction, hyper/hypotension, hypersensitivity/allergic reaction, ischemia, liver decompensation, mortality, obstruction, reproductive sterility, respiratory failure/arrest, urinary retention.